Table of Contents
1. EXECUTIVE SUMMARY
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Primary Research
3.3. Secondary Research
3.4. Market Size Estimation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.2.1. Growing Prevalence of Diabetes
4.2.2. Increasing number of clinical trials
4.2.3. Patent expiry of biologics paving way for biosimilars
4.3. Restraints
4.3.1. High cost of production
4.3.2. Stringent approval process for biosimilars
4.4. Opportunities
4.4.1. New product approval and launch
4.4.2. Strategic collaboration for product development
5. MARKET FACTOR ANALYSIS
5.1. Porterโs Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis/Supply Chain Analysis
5.2.1. Impact of COVID 19 on insulin biosimilars market
5.2.2. Impact on availability Of Drugs And API
5.2.3. Impact on the ongoing clinical trials
5.2.4. Impact on cost of product/therapy
5.2.5. Impact on trade (import/export)
6. GLOBAL INSULIN BIOSIMILARS MARKET, BY TYPE
6.1. Overview
6.2. Rapid-acting Biosimilars
Market Estimates & Forecast, by Region, 2020โ2027
Market Estimates & Forecast, by Country, 2020โ2027
6.3. Long-acting Biosimilars
Market Estimates & Forecast, by Region, 2020โ2027
Market Estimates & Forecast, by Country, 2020โ2027
6.4. Premixed Biosimilars
Market Estimates & Forecast, by Region, 2020โ2027
Market Estimates & Forecast, by Country, 2020โ2027
7. GLOBAL INSULIN BIOSIMILARS MARKET, BY INDICATION
7.1. Overview
7.2. Type I Diabetes
Market Estimates & Forecast, by Region, 2020โ2027
Market Estimates & Forecast, by Country, 2020โ2027
7.3. Type II Diabetes
Market Estimates & Forecast, by Region, 2020โ2027
Market Estimates & Forecast, by Country, 2020โ2027
8. GLOBAL INSULIN BIOSIMILARS MARKET, BY REGION
8.1. Overview
8.2. Americas
8.2.1. North America
8.2.1.1. US
8.2.1.2. Canada
8.2.2. Latin America
8.3. Europe
8.3.1. Western Europe
8.3.1.1. Germany
8.3.1.2. France
8.3.1.3. Italy
8.3.1.4. Spain
8.3.1.5. UK
8.3.1.6. Rest of Western Europe
8.3.2. Eastern Europe
8.4. Asia-Pacific
8.4.1. Japan
8.4.2. China
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle East & Africa
8.5.1. Middle East
8.5.2. Africa
9. COMPANY LANDSCAPE
9.1.1. Overview
9.1.2. Competitive Analysis
9.1.3. Market Share Analysis
9.1.4. Major Growth Strategy in the global insulin biosimilars market
9.1.5. Competitive Benchmarking
9.1.6. Leading Player in terms of Number of Developments in the global insulin biosimilars market
9.1.7. Key Developments & Growth Strategies
9.1.7.1. Product Launch
9.1.7.2. Merger & Acquisition
9.1.7.3. Joint Ventures
9.1.8. Major Players Financial Matrix
9.1.8.1. Sales & Operating Income 2019
9.1.8.2. Major Players R&D Expenditure 2019
10. COMPANY PROFILES
10.1. Sanofi S.A.
10.1.1. Company Overview
10.1.2. Product Type Overview
10.1.3. Financial Overview
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Boehringer Ingelheim
10.2.1. Company Overview
10.2.2. Product Type Overview
10.2.3. Financial Overview
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Eli Lilly & Co.
10.3.1. Company Overview
10.3.2. Product Type Overview
10.3.3. Financial Overview
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. NOVO Nordisk A/S
10.4.1. Company Overview
10.4.2. Product Type Overview
10.4.3. Financial Overview
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Biocon
10.5.1. Company Overview
10.5.2. Product Type Overview
10.5.3. Financial Overview
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Merck & Co.
10.6.1. Company Overview
10.6.2. Product Type Overview
10.6.3. Financial Overview
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Mylan N.V.
10.7.1. Company Overview
10.7.2. Product Type Overview
10.7.3. Financial Overview
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Pfizer Inc.
10.8.1. Company Overview
10.8.2. Product Type Overview
10.8.3. Financial Overview
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Sandoz
10.9.1. Company Overview
10.9.2. Product Type Overview
10.9.3. Financial Overview
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Fresenius Kabi
10.10.1. Company Overview
10.10.2. Product Type Overview
10.10.3. Financial Overview
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
10.11. Others
10.11.1. Company Overview
10.11.2. Product Type Overview
10.11.3. Financial Overview
10.11.4. Key Developments
10.11.5. SWOT Analysis
10.11.6. Key Strategies
11. APPENDIX
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 GLOBAL INSULIN BIOSIMILARS MARKET SYNOPSIS, 2020โ2027
TABLE 2 GLOBAL INSULIN BIOSIMILARS MARKET ESTIMATES & FORECAST, 2020โ2027 (USD MILLION)
TABLE 3 GLOBAL INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 4 GLOBAL INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 5 GLOBAL INSULIN BIOSIMILARS MARKET, BY REGION, 2020โ2027 (USD MILLION)
TABLE 6 NORTH AMERICA: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 7 NORTH AMERICA: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 8 US: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 9 US: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 10 CANADA: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 11 CANADA: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 12 LATIN AMERICA: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 13 LATIN AMERICA: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 14 EUROPE: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 15 EUROPE: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 16 WESTERN EUROPE: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 17 WESTERN EUROPE: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 18 EASTERN EUROPE: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 19 EASTERN EUROPE: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 20 ASIA-PACIFIC: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 21 ASIA-PACIFIC: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA: INSULIN BIOSIMILARS MARKET, BY TYPE, 2020โ2027 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA: INSULIN BIOSIMILARS MARKET, BY INDICATION, 2020โ2027 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL INSULIN BIOSIMILARS MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL INSULIN BIOSIMILARS MARKET
FIGURE 4 GLOBAL INSULIN BIOSIMILARS MARKET SHARE, BY TYPE, 2019 (%)
FIGURE 5 GLOBAL INSULIN BIOSIMILARS MARKET SHARE, BY INDICATION, 2019 (%)
FIGURE 6 GLOBAL INSULIN BIOSIMILARS MARKET SHARE, BY REGION, 2019 (%)
FIGURE 7 AMERICAS: INSULIN BIOSIMILARS MARKET SHARE BY REGION, 2019 (%)
FIGURE 7 NORTH AMERICA: INSULIN BIOSIMILARS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 8 EUROPE: INSULIN BIOSIMILARS MARKET SHARE, BY REGION, 2019 (%)
FIGURE 9 WESTERN EUROPE: INSULIN BIOSIMILARS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 10 ASIA-PACIFIC: INSULIN BIOSIMILARS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 11 MIDDLE EAST & AFRICA: INSULIN BIOSIMILARS MARKET SHARE, BY COUNTRY, 2019 (%)
FIGURE 12 GLOBAL INSULIN BIOSIMILARS MARKET: COMPANY SHARE ANALYSIS, 2019 (%)
FIGURE 13 SANOFI S.A.: KEY FINANCIALS
FIGURE 14 SANOFI S.A.: SEGMENTAL REVENUE
FIGURE 15 SANOFI S.A.: REGIONAL REVENUE
FIGURE 16 BOEHRINGER INGELHEIM: KEY FINANCIALS
FIGURE 17 BOEHRINGER INGELHEIM: SEGMENTAL REVENUE
FIGURE 18 BOEHRINGER INGELHEIM: REGIONAL REVENUE
FIGURE 19 ELI LILLY & CO.: KEY FINANCIALS
FIGURE 20 ELI LILLY & CO.: SEGMENTAL REVENUE
FIGURE 21 ELI LILLY & CO.: REGIONAL REVENUE
FIGURE 22 NOVO NORDISK A/S: KEY FINANCIALS
FIGURE 23 NOVO NORDISK A/S: SEGMENTAL REVENUE
FIGURE 24 NOVO NORDISK A/S: REGIONAL REVENUE
FIGURE 25 BIOCON: KEY FINANCIALS
FIGURE 26 BIOCON: SEGMENTAL REVENUE
FIGURE 27 BIOCON: REGIONAL REVENUE
FIGURE 28 MERCK & CO.: KEY FINANCIALS
FIGURE 29 MERCK & CO.: SEGMENTAL REVENUE
FIGURE 30 MERCK & CO.: REGIONAL REVENUE
FIGURE 31 MYLAN N.V.: KEY FINANCIALS
FIGURE 32 MYLAN N.V.: SEGMENTAL REVENUE
FIGURE 33 MYLAN N.V.: REGIONAL REVENUE
FIGURE 34 PFIZER INC.: KEY FINANCIALS
FIGURE 35 PFIZER INC.: SEGMENTAL REVENUE
FIGURE 36 PFIZER INC.: REGIONAL REVENUE
FIGURE 37 SANDOZ: KEY FINANCIALS
FIGURE 38 SANDOZ: SEGMENTAL REVENUE
FIGURE 39 SANDOZ: REGIONAL REVENUE
FIGURE 40 FRESENIUS KABI: KEY FINANCIALS
FIGURE 41 FRESENIUS KABI: SEGMENTAL REVENUE
FIGURE 42 FRESENIUS KABI: REGIONAL REVENUE